What is the primary mechanism of action for Meglitinides?

Meglitinides primarily function by stimulating insulin secretion from the pancreas. This class of medication works by binding to specific receptors on the beta cells of the pancreas, leading to an increase in insulin release in response to meals. This mechanism is particularly useful for managing blood sugar levels in individuals with type 2 diabetes, as it helps to lower postprandial (after-meal) blood glucose levels.

The effectiveness of Meglitinides is characterized by their rapid onset and short duration of action, allowing for flexibility in managing insulin levels around meal times. This action makes them distinct from other diabetes medications that might focus on different pathways, such as improving insulin sensitivity or affecting glucose production in the liver. In this context, stimulating insulin secretion directly addresses the issue of inadequate insulin response associated with type 2 diabetes.